Citigroup’s Vivos Therapeutics VVOS Stock Holding History

Citigroup’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$1	–	6290
2026 Q1	$1	Hold	1	–	–	﹤0.01%	5877
2025 Q4	$2	Hold	1	–	–	﹤0.01%	5946
2025 Q3	$3	Buy	+1	New	+$5	﹤0.01%	6011

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Citigroup's VVOS Position: Q2 2026 in Review

Citigroup sold out of Vivos Therapeutics (VVOS) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in VVOS in Q3 2025 and held it in 3 quarters. The position peaked at $3 in Q3 2025. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Citigroup reported no remaining Vivos Therapeutics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 Vivos Therapeutics share in Q2 2026, an estimated $1.
Citigroup first reported a position in Vivos Therapeutics in Q3 2025 and held it in 3 quarters.
Citigroup's Vivos Therapeutics position peaked at $3 in Q3 2025.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.